QurieGen and Rayca Precision launch integrated drug discovery workflow

QurieGen and Rayca Precision announced a partnership on Nov. 3, 2026, to connect target discovery, AI-guided molecular design and cellular validation in one early-stage R&D workflow. The companies say the approach is meant to give drug developers stronger biological evidence before key go-or-no-go decisions.

Why it matters: - Drug discovery still loses many candidates because of poor efficacy. - The partnership is designed to reduce uncertainty earlier by tying target selection, molecule design and experimental validation together. - The workflow could help teams work on harder targets, study treatment resistance and reconstruct mechanisms of action.

What happened: - QurieGen and Rayca Precision announced a strategic partnership on Nov. 3, 2026, in Nijmegen, Netherlands. - The companies introduced an integrated drug discovery workflow for pharmaceutical R&D. - The companies also published a joint white paper describing the approach. Read the joint white paper - QurieGen and Rayca Precision are inviting pharmaceutical and biotech R&D teams to discuss pilot projects. - QurieGen will attend BIO-Europe in Cologne from Nov. 9 and is available for partnering meetings.

The details: - QurieGen starts the workflow by studying disease biology and identifying potential targets with its time-resolved single-cell multi-omics platform. - The platform measures gene expression, surface and intracellular proteins, and phosphoprotein signaling in individual cells over time. - QurieGen uses those data to show how cells respond to perturbations, which pathways are affected and which mechanisms remain active despite treatment. - Rayca Precision uses those biological findings to guide molecular design. - Rayca models how proteins move and change shape to identify binding sites, including temporarily accessible sites. - Rayca combines AI with physics-based simulations to prioritize molecules that fit the biological hypothesis. - The design approach can support protein inhibition, degradation or other cellular responses. - Selected molecules are synthesized by the drug developer or an agreed partner. - QurieGen then tests the molecules in disease-relevant cellular models. - QurieGen measures molecular and cellular changes to see whether a molecule produces the intended biological response and to examine its mechanism of action. - If results differ from expectations, the data can help distinguish whether the issue is the target, the proposed mechanism or the molecule. - Those findings feed back into Rayca's next design cycle. - The offering focuses on early discovery and does not replace safety testing, development work or clinical trials. - QurieGen describes itself as a Dutch TechBio company developing virtual cell models for drug discovery. - QurieGen combines single-cell multi-omics, biological data and causal AI for target discovery, validation and disease-biology research. - Rayca Precision says it builds molecular intelligence for drug design using program data, physics-based simulation and generative methods.

Between the lines: - The partnership reflects a move away from treating target discovery, design and validation as separate stages. - A continuous feedback loop can make early-stage R&D more evidence-based and may lower the risk of advancing weak hypotheses. - The pilot structure suggests the companies want to make the workflow accessible without requiring a large proprietary dataset upfront. - The drug developer keeps decision-making authority over what advances, changes direction or stops.

What's next: - The companies plan to run pilot projects with pharma and biotech teams. - QurieGen will use BIO-Europe in Cologne as a venue for partnering discussions. - The joint workflow will be tested in early discovery settings before any broader adoption. - Future development will still require the standard safety, preclinical and clinical steps needed to determine patient benefit.